Calamos Advisors
CTIC

Calamos Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Calamos Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-233,452
Closed -$1.36M – 1588
2022
Q3 		$1.36M Buy
+233,452
New +$1.45M 0.01% 916

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Calamos Advisors's CTIC Position: Q4 2022 in Review

Calamos Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 233,452 shares — an estimated $1.36M sold.

Calamos Advisors first reported a position in CTIC in Q3 2022 and held it in 1 quarter. The position peaked at $1.36M in Q3 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • Calamos Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • Calamos Advisors sold 233,452 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $1.36M.
  • Calamos Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 1 quarter.
  • Calamos Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.36M in Q3 2022.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.